Black Diamond Therapeutics Inc BDTX-1535 Interim Results Call Transcript
Good morning, everyone, and thank you for joining us today to review our clinical update on the BDTX 1535 from the Phase 1 dose escalation trial. Earlier this morning, Black Diamond issued a press release outlining the data. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website at www.bdtx.com.
With me on the call today from Black Diamond are Dr. David Epstein, Co-Founder, President and Chief Executive Officer; Dr. Elizabeth Buck, Co-Founder and Chief Scientific Officer; Dr. Sergey Yurasov, Chief Medical Officer, and myself, Fang Ni Chief Business and Financial Officer. We will also be joined by Dr. Melissa Johnson lead investigator of the BDTX-1535 trial and Director of the lung cancer research at the Sarah Cannon Institute at Tennessee Oncology.
Before we get started, I would like to remind everyone that statements we make on this conference call will include forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |